Related Experiment Video
Updated: Sep 27, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Elevated BTG2 improves the radiosensitivity of non-small cell lung cancer (NSCLC) through apoptosis
Changchun Zhu1, Songling Zhang1, Aiying Xue1
1Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Background:
To identify radio-responsive genes and explore the biological function of encoded proteins in non-small cell lung cancer (NSCLC).
Methods:
Radio-responsive genes in irradiated H460 cells were screened from microarray data deposited in the Gene Expression Omnibus (GEO) database. A quantitative real time polymerase chain reaction assay was used to detect the expression of candidate radio-responsive genes in irradiated cells. CCK-8 assay, EDU assay, clone formation assay, immunofluorescence and flow cytometry were conducted to evaluate the biological function of B cell translocation gene 2 (BTG2) in NSCLC.
Results:
Bioinformatic analysis using GES20549 showed that BTG2 was a radio-responsive gene in irradiated H460 cells. The mRNA expression level of BTG2 was lower in H460 cells compared with that in BEAS-2B normal lung epithelial cells. BTG2 expression was elevated upon IR exposure, in a dose-dependent but not a time-dependent manner. CCK-8 and EDU assays revealed that BTG2 overexpression inhibited the growth rate of irradiated cells. Clone formation showed that elevated BTG2 promoted DNA damage of irradiated H460 cells. The number of γ-H2AX foci induced by DNA damage was also markedly increased upon BTG2 overexpression. Flow cytometry showed that BTG2 increased IR-induced cell apoptosis.
Conclusions:
BTG2 may be a novel radio-responsive factor and a promising therapeutic target for radiotherapy of NSCLC.
Insights
B cell translocation gene 2 (BTG2) is a novel radio-responsive gene in non-small cell lung cancer (NSCLC). Overexpression of BTG2 inhibits cancer cell growth and promotes DNA damage, suggesting its potential as a therapeutic target for NSCLC radiotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Radiotherapy
Background:
- Non-small cell lung cancer (NSCLC) remains a significant health challenge.
- Identifying genes that respond to radiation is crucial for improving NSCLC treatment.
- Understanding the role of specific genes in radio-resistance is key to developing targeted therapies.
Purpose of the Study:
- To identify radio-responsive genes in NSCLC.
- To investigate the biological function of B cell translocation gene 2 (BTG2) in NSCLC.
- To explore BTG2 as a potential therapeutic target for NSCLC radiotherapy.
Main Methods:
- Microarray analysis of irradiated H460 cells from the GEO database.
- Quantitative real-time polymerase chain reaction (qPCR) to detect gene expression.
- Cell proliferation (CCK-8, EDU), clone formation, immunofluorescence, and flow cytometry assays to assess BTG2 function.
Main Results:
- Bioinformatic analysis identified BTG2 as a radio-responsive gene in irradiated H460 cells.
- BTG2 expression was lower in NSCLC cells than normal lung cells and increased with radiation dose.
- BTG2 overexpression inhibited cell growth, promoted DNA damage, and increased apoptosis in irradiated NSCLC cells.
Conclusions:
- BTG2 is a novel radio-responsive gene in NSCLC.
- BTG2 plays a significant role in cellular response to radiation.
- BTG2 represents a promising therapeutic target for enhancing NSCLC radiotherapy.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...